BWAY

BWAY

BrainsWay Ltd. American Depositary Shares

$11.730+0.000 (0.000%)

Echtzeitkurs

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$11.730

Hoch

$11.730

Tief

$11.730

Volumen

0.02M

Unternehmensfundamentaldaten

Handelsstatistiken

KI-Analysebericht

Zuletzt aktualisiert: 24. Mai 2025
KI-generiertDatenquelle: Yahoo Finance, Bloomberg, SEC

BWAY: BrainsWay Ltd. American Depositary Shares – Unpacking Recent Trends and Future Signals

Stock Symbol: BWAY Generate Date: 2025-05-24 17:40:31

Let's break down what's been happening with BrainsWay and what the data might be telling us.

Recent News Buzz: What's the Vibe?

The news around BrainsWay lately has a pretty positive feel. Back in March, HC Wainwright & Co., an analyst firm, reiterated their "Buy" rating on the stock and kept a $16 price target. That's a strong vote of confidence from a professional observer. Before that, in late February, the company announced it would be reporting its fourth-quarter and full-year 2024 financial results. While the results themselves weren't in the news, the announcement itself often builds anticipation. When an analyst maintains a "Buy" and a solid price target after such an announcement, it suggests they're expecting good things or at least see continued value.

Price Check: What's the Stock Been Doing?

Looking at the last 30 days, BrainsWay's stock has seen some interesting moves. It started around the $10.75 mark in late February, dipped a bit, then saw a noticeable jump around mid-March, hitting $10.30 on March 12th, right when that analyst news came out. After that, it drifted lower through April, even touching the low $8s.

However, something shifted in May. The stock has been on a clear upward climb, moving from the high $8s to its current price of $10.73. This recent surge is quite strong. The AI model predicts today's price change will be flat (0.00%), but it sees a positive outlook for the next two days: a 1.85% increase for tomorrow and another 2.07% the day after. This suggests the recent upward momentum might continue.

Outlook & Ideas: Putting It All Together

Given the positive analyst sentiment, the recent strong upward price trend, and the AI's optimistic short-term predictions, the situation for BWAY appears to lean positive right now. The stock has broken out of its April slump and is showing clear bullish momentum.

  • Potential Entry Consideration: If you're looking at BWAY, the current price around $10.73 seems to be a key area. The AI model's technical analysis points to a potential buying opportunity near the support level of $10.62. This aligns with the idea that the stock is in an upward trend. A slight dip towards $10.63 or $10.80 could be considered as potential entry points, as suggested by the AI's recommendation data.
  • Potential Exit/Stop-Loss Consideration: For managing risk, a stop-loss around $9.63 might make sense. This level is below recent lows and could act as a signal to cut losses if the upward trend unexpectedly reverses. On the upside, the AI projects an upward trend with a potential target price of $1.01 (likely a typo in the provided data, perhaps meant to be a percentage or a higher dollar value, but the general sentiment is upward). The recommendation data also suggests a take-profit level of $10.94, which is just above the current price, indicating a short-term target if the momentum continues.

Company Context

BrainsWay operates in the Medical Devices sector, specifically focusing on noninvasive neurostimulation treatments for mental health disorders. They're a global leader in this niche. This means their performance is tied to advancements and adoption in mental health treatment technologies. The company's relatively small size (120 employees, $202 million market cap) and lower average trading volume (around 42,844 shares) mean its stock can sometimes be more volatile or react more sharply to news, both good and bad. The P/E ratio is quite high at 107.3, which suggests investors are paying a premium for future growth, but the revenue growth at 26.8% is noted as lower than expected, and Return on Equity is also below desired thresholds. These are fundamental points to keep in mind, even with positive short-term signals.


Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Investing in stocks involves risks, and past performance is not indicative of future results. Always conduct your own thorough research or consult with a qualified financial professional before making any investment decisions.

Ähnliche Nachrichten

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay with a Buy and maintains $16 price target.

Mehr anzeigen
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target
GlobeNewswire

BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)

BURLINGTON, Mass. and JERUSALEM, June 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today

Mehr anzeigen
BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD)
GlobeNewswire

BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego

BURLINGTON, Mass. and JERUSALEM, June 10, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, proudly

Mehr anzeigen
BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BrainsWay with a Buy and maintains $16 price target.

Mehr anzeigen
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target
GlobeNewswire

BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC

BURLINGTON, Mass. and JERUSALEM, June 04, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental

Mehr anzeigen
BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC

KI-VorhersageBeta

KI-Empfehlung

Bullisch

Aktualisiert am: 12. Juni 2025, 11:14

BärischNeutralBullisch

62.3% Konfidenz

Risiko & Handel

Risikostufe3/5
Mittleres Risiko
Geeignet für
Wachstum
Handelsleitfaden

Einstiegspunkt

$11.69

Gewinnmitnahme

$13.29

Stop-Loss

$10.57

Schlüsselfaktoren

PDI 23.0 liegt über MDI 20.7 mit ADX 17.1, was auf einen bullischen Trend hindeutet
Aktueller Preis ist extrem nah am Unterstützungsniveau ($11.69), was auf eine starke Kaufgelegenheit hindeutet
MACD -0.0294 liegt über der Signallinie -0.0365, was auf einen bullischen Crossover hindeutet

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.